Onco Actu du 12 mai 2015

	2. Etiologie
Study Links Father’s Age and Risk of Blood Cancer as an Adult [ACS] The authors say it is possible that the combination of having an older father and no siblings may promote cell proliferation in those individuals with an underdeveloped immune system and, as such, favors the development of cancers related to the immune system, like lymphoma.
Men with high oestrogen more likely to develop breast cancer [The Telegraph] It is the first time oestrogen circulating in the blood has been positively linked to male breast cancer, a rare condition affecting around 350 men a year in the UK.
	3. Prévention
Does Sugar Feed Cancer? [Dana-Farber Cancer Institute] Let’s look at some information about the link between sugar and cancer and what steps you can take to use healthy eating as a tool to lower your risk.
	4.12 Biopsies liquides
Liquid biopsies could revolutionize cancer care [The Globe and Mail] The huge potential for these tests is clear. The problem: There are no big, definitive studies to show they help patients, how accurate they are, which type is best or who should get them and when.
	4.9 Dép., diag. & prono. - Sein
St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX® as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit [Genomic Health] The clinical validation studies of Oncotype DX in early-stage breast cancer have shown that the Recurrence Score is prognostic and predicts the benefit of adding chemotherapy at diagnosis with long-term follow-up of 10 years.
Informing Decision-Making About Mammography Screening [The ASCO Post] The plethora of studies on the topic and the repeated citation of a few high-profile estimates have given us a false sense of security about the estimated frequency of overdiagnosis. In fact, most published estimates are either biased, misinterpreted, or both.
	5. Traitements
Combined radiation and hormonal therapy improves survival in node-positive prostate cancer [Massachusetts General Hospital] Study of large national database reveals that combination therapy reduced death risk by 50 percent, compared with hormone therapy alone.
Cuba Has a Lung Cancer Vaccine—And America Wants It [WIRED] How did Cuba end up with a cutting edge immuno-oncology drug? Though the country is justly famous for cigars, rum, and baseball, it also has some of the best and most inventive biotech and medical research in the world.
New Use for Old Tools Against Ovarian Cancer [Wall Street Journal] The approach doesn’t involve a hot new drug or technology. Instead, it’s based on being smarter about using the longtime mainstay treatments for ovarian cancer: surgery and chemotherapy.
	5.2 Pharma
Bioethics expert guides pharma firm on who gets its experimental drugs [Nature News & Comment] I don’t know what will happen if someone has a real adverse event and dies. Since these people are all pretty sick, I don’t think we’ll see a lot of liability. If someone died, there might be a FDA investigation to look at whether the drug had a role, but these aren’t people who attract lawyers.
	5.2.1 Pharma - Partenariats
Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies [Lilly] Under the terms of the agreement, BioNTech will receive a $30 million signing fee. For each potential medicine, BioNTech could receive over $300 million in development, regulatory and commercial milestones.
	5.2.2 Pharma - Fusions & Acquisitions
Juno Therapeutics Strengthens Multiple Capabilities Through Acquisition of Stage Cell Therapeutics [Juno Therapeutics] The acquisition provides Juno access to transformative cell selection and activation capabilities, next generation manufacturing automation technologies, enhanced control of its supply chain, and lower expected long-term cost of goods.
	5.5 ASCO
AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting [AbbVie] Notably, data will be presented from investigational studies of venetoclax, a B-cell lymphoma-2 (BCL-2) selective inhibitor, in relapsed or refractory multiple myeloma (R/R MM) patients, and veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, in advanced non-small cell lung cancer (NSCLC) patients with a history of smoking.
Experts Debate: Can We Cure Metastatic Breast Cancer? [The ASCO Post] Drs. Sledge and Hudis agreed that these two perspectives may relate to how one defines “cure.” With a “statistical cure,” no patient relapses and no patient dies. To the patient, a “personal cure” means death from something other than breast cancer, Dr. Sledge said, adding, “The latter definition is the fruitful one for the patient.”
	6. Lutte contre les cancers
ASCO Issues Updated, Expanded Set of Survivorship Care Planning Templates [ASCO] All told, the six ASCO disease-specific survivorship care plan templates cover more than 50 percent of all cancer diagnoses.
Want Precision Medicine? Share Your Data [Forbes] The good news is that this is a cultural problem, not a scientific one; and, as we are seeing, one that can be fixed with strong partnerships.
Newport proton beam centre to treat 700 patients a year [BBC News] The first cancer patients to get proton beam therapy at a UK centre will be treated in Newport by Christmas 2016.
	6.10 Politiques
Pricey new hepatitis C and cancer drugs make Essential Medicines List [Science] Magrini describes the list as “a flag” from a neutral party that a “cost-effective” drug is of little use if countries cannot afford it. “This speaks to a need to redefine what cost effectiveness means,” Magrini says. “It’s not a part of the solution. It’s part of the problem.”
Per-Anders Abrahamsson: Patients want us to work as a team [Cancer World] “Time is so short, it’s crazy. There are too many super-egos among doctors, politicians, CEOs. You find them everywhere. They have to downsize their egos. We need to sit down peacefully together, not fight each other.”
	6.11 Patients
Cured From Cancer, Almost [NY Times] Is it fair of me, though, to continue to burden them with this threat of relapse, to hold the sword of Damocles over their heads, when we all know how special it is to reach this five-year mark?
	6.6 Publications
NIH cancer paper retracted for faked data [Retraction Watch] The journal retracted the paper following an investigation into author Stephanie K. Watkins, then a postdoctoral fellow at the National Cancer Institute.